Reducing the proliferation of carcinoma cells by administration of a poly-oxygenated metal hydroxide

• US 10,278,988 B2
• Filed: 05/18/2018
• Issued: 05/07/2019
• Est. Priority Date: 03/30/2016
• Status: Active Grant

• Current Assignee: Baylor University
• Original Assignee: Baylor University
• Inventors: Bruce, Erica D., Woodmansee, Jr., John W.
• Primary Examiner(s): Arnold, Ernst V
• Assistant Examiner(s): Chang, Kyung S
• Application Number:
  US15/983,922
• Publication Number:
  US 20180264034A1
• Time in Patent Office: 354 Days
• Field of Search: None
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/08 Oxides; Hydroxides
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/52 the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
• CPC Class Codes: A61K 47/6921 the form being a particulate, a powder, an adsorbate, a bead or a sphere
• CPC Class Codes: A61K 47/6923 the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
• CPC Class Codes: A61K 47/6949 inclusion complexes, e.g. clathrates, cavitates or fullerenes
• CPC Class Codes: A61K 9/0026 Blood substitute; Oxygen transporting formulations; Plasma extender
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00

Abstract

A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O₂) molecules. The carcinoma cells may comprise prostrate carcinoma (22Rv1). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid.

Claims

1. A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated aluminum hydroxide composition to the mammal in need thereof to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated aluminum hydroxide composition comprises a clathrate containing fee oxygen gas (O₂) molecules;

and wherein the therapeutically effective amount of the poly-oxygenated aluminum hydroxide composition ranges from 10 mg/L to 1000 mg/L.

2. The method as specified in claim 1 wherein the carcinoma cells comprise prostrate carcinoma (22Rv1).

3. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide material is configured to provide bioavailable oxygen gas molecules to the mammal when administered to the mammal.

4. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition is administered intravenously.

5. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition is administered directly to the hypoxic carcinoma cells.

6. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition is administered orally.

7. The method as specified in claim 1 wherein the composition comprises a fluid.

8. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition is soluble in the fluid.

9. The method as specified in claim 7 wherein the fluid is a phosphate buffered saline (PBS).

10. The method as specified in claim 7 wherein the fluid is lactated ringers solution (LRS).

11. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition comprises poly-oxygenated aluminum hydroxide particles all having a diameter of less than or equal to 10 um.

12. The method as specified in claim 11 wherein the poly-oxygenated aluminum hydroxide particles particles are homogeneous.

13. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition comprises poly-oxygenated aluminum hydroxide particles all having a diameter of less than or equal to 1 um.

14. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition comprises poly-oxygenated aluminum hydroxide particles that are surface modified.

15. The method as specified in claim 14 wherein the poly-oxygenated aluminum hydroxide particles comprises particles that are surface modified with polyethylene glycol (PEG).

16. The method as specified in claim 1 wherein the mammal is a human individual.